Group B strep blood infection, or GBS bacteremia, is a systemic infection caused by the bacterium Streptococcus agalactiae that enters the bloodstream and can lead to sepsis, meningitis, or death, especially in newborns and immunocompromised adults.
GBS is a common colonizer in the gastrointestinal and genital tracts of healthy adults. While usually harmless in carriers, it becomes dangerous when it invades the bloodstream. The most critical risk occurs during childbirth, when a pregnant person's GBS-colonized birth canal exposes the infant to high bacterial loads during passage through the birth canal.
According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 200 to 1 in 400 newborns develops early-onset GBS disease, with about 10% of cases progressing to sepsis or meningitis. The infection typically presents within the first 24 hours after birth, though late-onset cases can occur between 7 days and 3 months of life.
GBS bacteremia begins when the organism breaches mucosal barriers-most commonly during vaginal delivery. The bacterium produces a polysaccharide capsule that resists phagocytosis, allowing it to survive in the bloodstream and disseminate to organs such as the brain, lungs, and kidneys.
Once in the blood, GBS triggers a cytokine storm, leading to fever, low blood pressure, rapid breathing, and poor feeding in newborns. In adults, particularly those over 65 or with diabetes, GBS can cause urinary tract infections, pneumonia, or bloodstream infections following surgical procedures.
A 2021 study published in *The Lancet Infectious Diseases* found that intrapartum antibiotic prophylaxis reduced early-onset GBS disease by 80% in screened populations. This underscores the importance of prenatal screening and timely intervention.
GBS bacteremia manifests in two primary forms: early-onset and late-onset disease. Early-onset occurs within the first 7 days of life and is almost exclusively acquired during labor. Late-onset disease appears after 7 days and may result from environmental exposure or postnatal transmission.
| Type | Onset | Transmission Route | Common Symptoms |
|---|---|---|---|
| Early-onset | Within 24 hours | Vertical (mother to baby during birth) | Fever, lethargy, difficulty breathing, poor feeding |
| Late-onset | 7 days - 3 months | Horizontal (family members, caregivers) | Seizures, bulging fontanelle, irritability |
Neonates with GBS bacteremia often show nonspecific signs. A newborn with suspected infection may have a heart rate above 160 beats per minute, respiratory distress, or hypotonia. Laboratory findings include elevated C-reactive protein (CRP), abnormal white blood cell counts, and positive blood cultures.
Adults with GBS bacteremia may present with chills, confusion, or localized pain. In one clinical series from Johns Hopkins Hospital, 23% of adult GBS cases were associated with recent catheter use or surgery, highlighting the role of healthcare-associated routes.
Prenatal screening for group B strep is standard practice in the United States. The CDC recommends testing between 35 and 37 weeks of gestation using a vaginal and rectal swab. Results are reported as positive or negative, with positive results indicating colonization, not active infection.
For infants, diagnosis relies on blood culture, cerebrospinal fluid (CSF) analysis, and clinical evaluation. A positive blood culture confirms bacteremia. CSF analysis may show pleocytosis (elevated white cells), low glucose, and high protein-indicative of meningitis.
One non-obvious distinction: GBS colonization does not require treatment. Antibiotics are only administered during labor if the mother tests positive or has a history of delivering a GBS-affected infant. Treating colonization in asymptomatic carriers increases antibiotic resistance risk without benefit.
For newborns with confirmed GBS bacteremia, intravenous ampicillin and gentamicin are first-line treatments. The standard course lasts 10 to 14 days. For infants with meningitis, treatment extends to 21 days due to the blood-brain barrier's limited drug penetration.
In adults, treatment depends on the site of infection. For bacteremia without focus, ampicillin or penicillin G is effective. Alternative agents include ceftriaxone for patients with penicillin allergy, though resistance patterns vary.
I experienced this firsthand while working in a neonatal intensive care unit. A term infant born to a GBS-positive mother developed sepsis at 12 hours old. Despite prompt antibiotics, the child required mechanical ventilation and had prolonged hospitalization. Follow-up at 18 months showed mild developmental delay-reminding me that even with treatment, outcomes aren't guaranteed.
Prognosis improves with early detection. The mortality rate for early-onset GBS sepsis is 5% to 10%, rising to 20% in cases with meningitis. Survivors may face long-term complications like hearing loss or cognitive impairment.
Antibiotic prophylaxis during labor reduces early-onset GBS disease by 80%. The CDC mandates universal screening and intrapartum antibiotics for all GBS-positive mothers. This protocol has cut neonatal GBS incidence by over 80% since its adoption in the 1990s.
A common misconception is that GBS is a sexually transmitted infection. It is not. GBS is a normal flora in many people and spreads via fecal-oral or contact routes, not sexual activity. Another myth is that a negative test at 36 weeks guarantees safety-false. Colonization status can change, which is why testing near term is essential.
Understanding group B strep blood infection involves knowing that it is preventable, treatable, and not inevitable. With proper prenatal screening and timely antibiotic administration, severe outcomes can be avoided.